Abstract
Trastuzumab (tras)-anns (KANJINTI™) is one of the first biosimilars of reference product (RP) Herceptin® approved in the European Union (EU) in May 2018, also approved in the United States in June 2019, for treatment of human epidermal growth factor receptor 2-positive (HER2+) early and metastatic breast cancer (BC) as well as metastatic gastric cancer. Study objectives were to define real-world characteristics of BC patients (pts) receiving tras-anns, their prior tras treatment patterns, and tras-anns safety.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
